Montreal researchers are taking part in an international clinical trial that evaluates a medication intended to postpone the onset of Alzheimer’s disease symptoms in individuals who exhibit early biological markers. The trial is being conducted in Montreal, Quebec, and was reported on 14 October 2026.
The study aims to determine whether the drug can delay symptom development, a key step as Alzheimer’s disease currently has no cure. Researchers are concentrating on early‑stage interventions in hopes of slowing the disease’s progression.